Cleo Diagnostics

Peer-Review Further Supports CLEO’s Ovarian Cancer Detection Technology

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of further data on its triage test for ovarian cancer.


Highlights

  • CLEO’s second peer-reviewed dataset has now been published in medical journal “Diagnostics”
  • The study concluded that CLEO’s test:
    • Correctly identified most cancer cases that were missed by the standard marker CA125;
    • Eliminated the majority of "false positive" results caused by CA125 use; and
    • Correctly identified the majority of patients with early-stage ovarian cancers.
  • Peer review validates CLEO’s technology and commercial strategy targeting the surgical triage market where accurate and early cancer identification is critical.
The article, entitled ‘Reclassification of patients with ambiguous CA125 for optimised pre-surgical triage’ was published in the peer reviewed medical journal, Diagnostics.

A copy of the publication is available here: https://www.mdpi.com/2075-4418/14/7/671

The article concluded:

a) CLEO’s test correctly identified most cancer cases missed by CA125, including a majority of patients with early stage cancers;

b) The test provided superior identification of benign disease to eliminate the majority of "false positive" results obtained using CA125; and

c) The test efficiently discriminated malignant from benign samples.

Commenting on the outcomes published, CLEO Chief Executive, Richard Allman, said:

“These results demonstrate that the CLEO ovarian cancer triage test is far superior to the current standard of care using the CA125 benchmark. Our test will improve the initial clinical investigation process, helping clinicians to triage patients far more effectively than current methods.

The ability to identify early-stage cancers also supports our ultimate goal of an ovarian cancer screening program using CLEO technology.

Our cancer detection technology is supported by a foundation of gold-standard scientific evidence. These publications will underpin regulatory approvals with the Food and Drug Administration (FDA) and will form a crucial part of CLEO’s market entry activities. They provide the required evidence for doctors to prescribe CLEO’s blood test and for reimbursement by health insurers.”


Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

COV:AU
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cleo Diagnostics

Cleo Diagnostics


Keep reading...Show less

Medtronic: Americans Favor Quality Over Quantity in Pursuit of Longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer - it's about living their healthiest, best lives. While most want to live to 90-well past the average U.S. life expectancy of 77.5 years-nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cardiex Limited

Cardiex Limited


Keep reading...Show less

Americans favor quality over quantity in pursuit of longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×